Slide 1: AngioDynamics Third Quarter 2023 Earnings Presentation
ANGIODYNAMICS Third Quarter 2023 Earnings Presentation March 30, 2023 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q3 and YTD FY23
Corporate Developments – Q3 and YTD FY23 Q3 Operational developments Positive cash flow from operations of $1.4 million Continued gross margin headwinds in raw material and labor inflation Backlog increased by $0.4 million to $5.4 million at quarter end due to certain component supplier delays Q3 re
Slide 4: Q3 and YTD FY23 Results (unaudited)
Q3 and YTD FY23 Results (unaudited) $ in thousands (except per share data) Q3 FY23 Q3 FY22 Change YTD FY23 YTD FY22 Change Revenue $80,712 $73,970 9.1% $247,678 $229,221 8.1% Med Tech Med Device $22,874 $57,838 $19,612 $54,358 16.6% 6.4% $70,193 $177,485 $56,106 $173,115 25.1% 2.5% United States Int
Slide 5: Q3 and YTD FY23 Results
Q3 and YTD FY23 Results 5 Med Device Med Tech 25.1% growth 2.5% growth YTD Revenue Growth YTD FY22 YTD FY23 YTD Revenue Contribution YTD FY22 YTD FY23 Med Device Med Tech 16.6% growth 6.4% growth Q3 Revenue Growth Q3 FY22 Q3 FY23 Q3 Revenue Contribution Q3 FY22 Q3 FY23
Slide 6: Sales Comparison to Prior-Year Periods
Sales Comparison to Prior-Year Periods 6 Med Tech Q3 FY23 YTD FY23 Auryon 42.8% 50.7% Thrombus Management* AngioVac AlphaVac** (0.7%) (15.7%) 199.4% 9.3% (8.2%) 347.9% NanoKnife® Disposables 22.2% 26.7% NanoKnife® Capital (45.6%) (13.0%) Med Device Q3 FY23 YTD FY23 Core Peripheral 13.8% 9.9% Venous
Slide 7: FY23 Guidance
FY23 Guidance 7 Prior Revised Revenue $342 - $348 million $338 - $342 million Gross Margin Med Tech Med Device 52.5% - 54.5% 65.0% - 68.0% 45.0% - 48.0% 51.0% - 52.0% 64.0% – 66.0% 45.0% - 48.0% (unchanged) Adjusted EPS $0.01 - $0.06 ($0.06) – ($0.01)
Slide 8: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 8
Slide 9: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustment to re